Open in interactive viewer → charts, metric popovers & call review

Scholar Rock's First Commercial Quarter: Demand Is Real, the Revenue Is 2027

ISEMBYLD shipped nine days after approval and 98% of scripts already run through the hub — but $0.6 million of revenue, a $205 million voucher sale and a stock 20% below its August high say the market is grading the plumbing, not the promise.
SRRK · Earnings Call · 2026-11-10

The six-hundred-thousand-dollar quarter

Scholar Rock reported its first commercial quarter after the FDA approved ISEMBYLD (apitegromab) on September 11, 2026 — well ahead of the PDUFA date. Revenue was $0.6 million, and management was almost apologetic in explaining why: that figure is initial inventory pushed into the specialty network, not patients on drug. Infusions only began in October, and the company went out of its way to reset expectations on timing rather than to celebrate demand. “we anticipate the majority of the patients who enrolled through October will begin infusions in 2027” — David Hallal, Chairman and Chief Executive Officer · 2026-11-10 That is the crux of this report. The clinical story — the first and only muscle-targeted therapy approved in SMA, a 2.2-point Hammersmith improvement on top of SMN2-targeted therapies — has been settled since approval. What is unsettled, and what the equity is now trading on, is the gap between demand signal and revenue recognition. Management is explicit that the bottleneck is not interest: “strong demand is outpacing reimbursement and access at this stage” — Robert Keith Woods, Chief Operating Officer · 2026-11-10 Analysts pressed hard on the shape of the curve — would 2027 open with a bolus of patients whose scripts are already sitting in the hub? COO Keith Woods pushed back on the framing rather than on the math:

I'd actually be more concerned if there was a bolus and then the level of enrollments let up. But as David stated, it's been consistent and steady on a week-over-week basis. We track these things not just on a weekly basis, but on a daily basis here.

Robert Keith Woods, Chief Operating Officer · 2026-11-10
That is a credible answer to a demand question and a non-answer to a revenue question, and the sell-side knows it. The company declined to quantify enrollment forms at all, offering only relative color: treatment-naive patients outnumbering patients rolling over from the early access and ONYX extension programs, more than a third of the top 140 SMA centers having enrolled patients, and 95% of those centers already engaged in six weeks — versus a stated norm of roughly four months.

What disappeared from the deck

For three consecutive quarters, this company's most prominent language was not about patients at all. It was about a fill/finish problem: fill/finish facility, inspection classification, second vialer, Form 483, remediation plan. In the second quarter of 2026 the single biggest spike in Scholar Rock's keyword set was Catalent Indiana. Last quarter, David Hallal was still telling investors the review was on track and that the alternate site carried the day.

There's no reason to believe the FDA can't get their work done in these next 55 days.

David Hallal, Board Chair and Chief Executive Officer · 2026-08-06
This quarter, Catalent Indiana is the company's single largest keyword decliner and the manufacturing vocabulary has essentially exited the prepared remarks. The resolution was administrative rather than triumphant: the European MAA was resubmitted in early October with the alternate fill/finish site in place of Catalent Indiana, validated, with a CHMP opinion expected in the first half of 2027. Nobody said "we dropped Catalent." The chart did it for them. That is the most important thing that changed in this report — not a new product claim, but the retirement of an eighteen-month-old overhang.

The plumbing of a first-in-class launch

What replaced the manufacturing anxiety is a vocabulary of reimbursement mechanics, and it is genuinely new for this name: J-code (filed immediately, effective April 1, 2027 — described as the shortest possible timeline), unspecified-code billing until then, hospital formulary approvals, prior authorizations, and appeals. Payer approvals have reached payers covering more than 90% of U.S. covered lives, and two of the largest — Anthem and Centene, 47 million lives combined — have published policies aligned with the label, with no age, type or ambulatory restriction. 98% of prescriptions are flowing through the support hub. The honest read is that the prescription-to-infusion interval of 60 to 90 days or longer is not a surprise to this management team. It was forecast on the August call by the same executive, in nearly the same words, months before approval. “the average time from prescription to a patient actually being able to get infused is greater than 60 days” — Robert Keith Woods, Chief Operating Officer · 2026-08-06 Where the company is genuinely ahead is reach — 95% of target centers engaged in six weeks — and where it is genuinely behind is cash conversion, which the J-code date hard-caps. April 1, 2027 is the nearest structural accelerant.

Cash, and a tape that already voted

Financially, this is a company that removed its financing risk in a single quarter without issuing a share. It ended Q3 with $413.6 million in cash and securities, sold its priority review voucher for $205 million in November, and unlocked an additional $150 million under its existing debt facility — allowing the CFO to claim funding "“without the need to access the capital markets at this time” — Vikas Sinha, Chief Financial Officer · 2026-11-10." That is a materially different posture from a year ago, when the financing conversation was about loan extensions and ATM usage. The filed numbers still show the pre-launch shape: at the last reported quarter, R&D ran at $58 million and net loss at $110 million. Q3 operating expenses were $106.6 million including $17.9 million of stock comp, or $88.7 million ex-SBC — the discipline claim holds. Effective net cash stood at $355 million at the last filing, translating to roughly seven quarters of runway. Leverage tells the same story from the other side: liabilities at 51.5% of assets, up twenty points year over year. And the tape has already rendered a verdict. SRRK is down 15% over the last 90 trading days and sits 20% below its August 26 high of $60.04 — a peak reached before the approval itself. Approval, in other words, was the sell-the-news event; the debate has moved from "will it be approved" to "when does $0.6 million become $60 million." The stock's long-run history is a sequence of violent alternating moves rather than a trend, which is exactly what a single-asset binary biotech looks like when the binary resolves.

The optionality nobody is paying for yet

The U.S. is 6,600 patients on SMN2 therapy in a 330-million-person market. Hallal's sequencing argument is that Germany (~80 million) follows in the second half of 2027 and Japan (~120 million) arrives near year-end 2027, where a single-payer system sets price within 60 to 90 days of approval and "everybody is insured" — no policy build-out, no formulary fight. He framed it as "“we pull in another 120 million population country” — David Hallal, Chairman and Chief Executive Officer · 2026-11-10," against roughly 35,000 treated SMA patients worldwide. Subcutaneous apitegromab, an under-two OPAL expansion and an FSHD Phase II sit behind that. None of that is in the price today, and it does not need to be. The near-term question is narrower and more mechanical: does the steady weekly enrollment rhythm convert into infusions once the April J-code lands and payer policies accumulate, or does the first-in-class reimbursement slog stretch the 2026-2027 revenue line by quarters? Management's answer — "a matter of when and not if" — is the right answer for patients and an unsatisfying one for a model. Six weeks post-approval, with the manufacturing shadow finally gone, this is now a pure execution story with a visible, dated catalyst. That is a better story than the one it replaces, even if the stock has not yet agreed.